Fusion Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Fusion Pharmaceuticals Inc. had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value of $120.24 million as of 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 · last filed 2024-05-07
- 2024-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $120.24M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $31.26M.
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $2.11M.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $8.21M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value |
|---|---|
| 2024-03-31 | $120.24M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $31.26M 10-K · filed 2024-03-20 |
| 2023-09-30 | $2.11M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $8.21M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $5.19M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.44M 10-K · filed 2023-03-16 |
| 2022-09-30 | $3.00M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.78M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $14.64M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $5.47M 10-K · filed 2022-03-17 |
| 2021-09-30 | $13.77M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $14.14M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $20.47M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $20.84M 10-K · filed 2021-03-25 |
| 2020-09-30 | $18.70M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $31.90M 10-Q · filed 2020-08-11 |